circRNA basic information
circBase ID: hsa_circ_0015497
Name: hsa_circ_QSOX1
Synonym: circQSOX1
Host Gene: QSOX1
Genomic location(hg19): chr1:180145065-180167169:+
Genomic location(hg38): chr1:180175930-180198034:+
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0005575
MONDO name: colorectal cancer
Disease details: colorectal cancer / CRC
Disease DO ID:
 5672, 9256
Disease MeSH ID:
 -
Disease NCIt ID:
 C4978
Disease ICD11 ID:
 -
Disease OMIM ID:
 114500
Species: Human
Species details: Homo sapiens
Tissue specimen:

CRC tissues; adjacent normal tissues; tumor tissues; xenograft tumor tissues
Cell lines:

NCM460; SW620; HCT116; LOVO; HT-29; CT26; MC38
In vivo animal model:

cell line-derived xenograft; syngeneic model
circRNA-disease information
Expression pattern:
UP
Associated gene: PGAM1, METTL3, IGF2BP1, IGF2BP2, Ago2 protein
Associated microRNA: miR-326, miR-330-5p
Biological function: Promotes CRC tumorigenesis, proliferation, migration, invasion, tumor growth, glycolysis, Treg cell-related immune escape, and resistance to anti-CTLA-4 therapy; inhibits apoptosis.
Molecular mechanism: METTL3-mediated m6A modification stabilizes circQSOX1 and is read by IGF2BP2; circQSOX1 acts as a ceRNA by sponging miR-326 and miR-330-5p to upregulate PGAM1, promoting glycolysis, lactic acid accumulation, Treg-mediated immune escape, and anti-CTLA-4 therapy resistance.
Biological pathway or process:

m6A modification (promotes); ceRNA regulation (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); glycolysis (promotes); immune regulation (promotes); drug resistance (promotes)
Detected method:
Q
M
Validation methods:

Microarray; RT-qPCR; Clinical Sample Validation; Cohort Study; Survival Analysis; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; MeRIP / MeRIP-seq; RNA Pull-Down; IF (Immunofluorescence); RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; Flow Cytometry（Non-apoptosis/cycle）; Bioinformatics Analysis
Clinical significance:

High circQSOX1 expression was associated with carcinogenesis and poor clinical outcome of CRC patients; higher circQSOX1 expression was associated with poorer overall survival and disease-free survival.
Description:

circQSOX1 is upregulated in CRC tissues and cells and high expression is associated with poor overall and disease-free survival. METTL3-mediated m6A modification stabilizes circQSOX1 through IGF2BP2, while circQSOX1 promotes CRC progression via the miR-326/miR-330-5p/PGAM1 ceRNA axis. This axis enhances glycolysis and lactic acid accumulation, promoting Treg-mediated immune escape and resistance to anti-CTLA-4 therapy.
Confidence score:

0.8892
Other information
Title:

N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: 2022
PubMed ID: 36370665
Study type:

combined biological and clinical study
Data availability: GSE172229; GSE126094; Supplementary data associated with this article can be found in the online version at doi:10.1016/j.drup.2022.100886
Code availability: -